# PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas

> **NCT06961565** · PHASE1 · RECRUITING · sponsor: **Pasithea Therapeutics Corp.** · enrollment: 56 (estimated)

## Conditions studied

- NF1 Mutation
- Neurofibroma Plexiform
- Neurofibroma, Plexiform
- Neurofibromatosis Type 1 (NF1)-Related Plexiform Neurofibromas (PNs)
- Neurofibromatosis Type 1 (NF1)

## Interventions

- **DRUG:** PAS-004 Tablets

## Key facts

- **NCT ID:** NCT06961565
- **Lead sponsor:** Pasithea Therapeutics Corp.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-30
- **Primary completion:** 2027-09
- **Final completion:** 2027-12
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2025-12-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06961565

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06961565, "PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06961565. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*